Ro 40–5967: A New Nondihydropyridine Calcium Antagonist

Cardiovascular Drug Reviews

Volumn 9, Issue 1, 1991, Pages 4-17

  Clozel, Jean‐Paul ^a   Osterrieder, Wolfgang ^a   Kleinbloesem, Cornells H ^a   Welker, Horst A ^a   Schläppi, Bernhard ^a   Tudor, Robert ^a   Hefti, Fridolin ^a   Schmitt, Rita ^a   Eggers, Herwig ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

calcium antagonists; coronary heart disease; hypertension; Ro 40 5967

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL; DEVAPAMIL; MIBEFRADIL; VERAPAMIL;

ANIMAL MODEL; CORONARY ARTERY DISEASE; DOG; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ELECTROPHYSIOLOGY; GUINEA PIG; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; REVIEW; VASODILATATION;

EID: 0025805345     PISSN: 08975957     EISSN: 15273466     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1991.tb00539.x     Document Type: Article

References (35)

1. The cardiovascular system
2. Toxicity study of MK 421 (enalapril maleate). III. Subacute and one‐year chronic studies in beagle dogs
3. Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics
4. Cardiotoxicity of adrenergic bronchodilator and vasodilating antihypertensive drugs
5. Cardiotoxicity studies with diazoxide, reserpine, guanethidine, and combinations of diazoxide and propranolol in dogs
6. Gingival overgrowth induced by diltiazem. A case report
7. Calcium channel blockers: pharmacologic considerations
8. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease
9. Effects of Ro 40–5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil
10. Effects of Ro 40–5967 and verapamil in rats without and with heart failure
11. Gingival hyperplasia caused by verapamil
12. Toxicologicai investigations with nisoldipine (summary of relevant studies)
13. Acute, subchronic and chronic toxicity of the new angiotensin‐converting enzyme inhibitor ramipril
14. Toxicity testing of antihypertensive drugs
15. Historical overview: the calcium channel of the heart
16. Pharmacokinetics and pharmacodynamic effects of aqueous diltiazem in healthy human
17. 2+ channel probe
18. Antihypertensive properties of the novel calcium antagonist (1S,2S)‐2‐[2[[3‐(2‐benzimidazolyl)propyl]metnylamino]ethyl]‐6‐fluoro‐l,2,3,4‐tetrahydro‐1‐isopropyl‐2‐naphthyl methoxyacetate dihydrochloride in rat models of hypertension
19. Nitrendipine‐induced gingival overgrowth in dogs
20. Acute cardiomyopathy induced by the vasodilating antihypertensive agent minoxidil
21. Gingival hyperplasia associated with nifedipine therapy
22. Renal effects of enalapril in dogs
23. Calcium channel antagonists. Part IV: Side‐effects and contraindications. Drug interactions and combinations
24. 2+ channel blocker with potent vasodilator but weak inotropic action
25. Calcium channel blockade in the management of severe chronic congestive heart failure: a bridge too far
26. Gingival hyperplasia caused by nifedipine–a preliminary report
27. Regional contractility: selective depression of ischemic myocardium by verapamil
28. The effect of diltiazem on mortality and reinfarction after myocardial infarction
29. Gingivai hyperplasia induced by nifedipine, an arterial vasodilating drug
30. Ro 40–5967, in contrast to diltiazem, does not reduce left ventricular function in rats with and without chronic myocardial infarction
31. Gingival hyperplasia in dogs induced by oxodipine, a calcium channel blocking agent
32. Ro 40–5967. Pharmacokinetics of a new calcium antagonist